Earnings Feed
Start Free
Magenta Therapeutics, Inc.·4

Dec 20, 5:52 PM ET

DAVIS JOHN C. JR 4

4 · Magenta Therapeutics, Inc. · Filed Dec 20, 2019

Insider Transaction Report

Form 4
Period: 2019-12-20
Magenta Therapeutics, Inc.MGTA
DAVIS JOHN C. JR
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2019-12-20$9.49/sh+114$1,082→ 8,418 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2019-12-20−805→ 236,239 total
    Exercise: $9.49Exp: 2028-04-25→ Common Stock (805 underlying)
  • Exercise/Conversion

    Common Stock

    2019-12-20$9.49/sh+805$7,639→ 9,223 total
  • Sale

    Common Stock

    2019-12-20$15.00/sh−919$13,785→ 8,304 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2019-12-20−114→ 236,125 total
    Exercise: $9.49Exp: 2028-04-25→ Common Stock (114 underlying)
Footnotes (2)
  • [F1]This trade is pursuant to an active 10b5-1 plan.
  • [F2]25% vested on February 16, 2019 with the remaining 75% vesting in 12 equal quarterly installments thereafter.

Documents

1 file
  • 4
    primarydocument.xmlPrimary

    PRIMARY DOCUMENT